Study PTG116878, a Dose-Optimization Study of Ezogabine/Retigabine Immediate Release Tablets Versus Placebo in the Adjunctive Treatment of Subjects With Partial-Onset Seizures

Trial Profile

Study PTG116878, a Dose-Optimization Study of Ezogabine/Retigabine Immediate Release Tablets Versus Placebo in the Adjunctive Treatment of Subjects With Partial-Onset Seizures

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 21 May 2014

At a glance

  • Drugs Retigabine (Primary)
  • Indications Partial epilepsies
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 17 May 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 26 Jan 2013 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database.
    • 26 Jan 2013 New source identified and integrated (EudraCT2012-003105-10: European Clinical Trials Database).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top